Surveillance Summary March 6 – 12, 2004
March 12, 2004 by admin · Leave a Comment
23 technologies were updated or added to the Biohorizon Emerging Health Technology Database in Week 11. This represents moderate activity and places Week 11 as the most active week so far in 2004. 2 of the updated technologies, Daxas and Acomplia, were designated as High Impact Health Technologies, 18 received a Moderate Impact score, while the remaining 3 were placed in the Low Impact category. The mean Biohorizon Impact Score for the week was 42, very much in line with the 2004 average. Please see the table below for this week’s Top Ten Technologies to watch.
Week at a Glance
Technologies updated this week in the BioHorizon database
Technology Company Target Disease Score
Daxas Altana COPD 78/100
Acomplia™ Sanofi Smoking cessation/Obesity 75/100
Xibrom Ista Pharmaceuticals Cataracts 59/100
DSC-104 Discovery Laboratories Asthma 53/100
Pexelizumab Alexion Myocardial Infarction 49/100
Aromasin Pfizer Breast Cancer 49/100
Fasudil Schering AG Angina 43/100
Faslodex Astra Zeneca Breast Cancer 43/100
RSR13 Allos Brain Cancer 42/100
Riquent LaJolla Lupus 42/100
